Initially utilized as treatment for premature ovarian insufficiency and more commonly for treatment of age related diminished reserve.
Perinatal risk among older women undergoing donor ooocyte in vitro fertilization reflects donor rather than recipient age.
Complication rate 0.7% and include ovarian hyperstimulation syndrome, hemorrhage and adverse anesthesia effects.